Heat Biologics has commenced a programme to develop a vaccine against Covid-19. Credit: Credit: leo2014 from Pixabay

Heat Biologics, a clinical-stage biopharmaceutical company, has commenced a programme within its fully-owned subsidiary, Zolovax, to develop a vaccine using its gp96 vaccine platform for fighting Covid-19.

It has filed a provisional patent for use of its technology platform for treating Covid-19.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

gp96 is a heat shock protein found in all human cells. It functions as a potent immune adjuvant that serves as “molecular warning system” to induce immunity against necrotic cells.

Naturally, gp96 is tethered to the cell and is normally released only during necrosis or cell death.

This vaccine platform reprogrammes live cells to continually secrete antigens bound to the gp96, thereby activating a strong T-cell response against those antigens.

Heat Biologics CEO Jeff Wolf said: “gp96 is a powerful vaccine platform that has been shown to induce a potent immune response and effectiveness in the induction of mucosal immunity in several infectious disease models. We believe this platform has the potential to provide broad protection against COVID-19, and possible future mutations of COVID-19 or other coronaviruses. We look forward to providing further updates on our progress as developments unfold.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The gp96 platform has undergone stringent testing in several National Institutes of Health (NIH) and US Department of Defense (DOD)-funded mice and primate trials as a vaccine against SIV/HIV, malaria, zika and other infectious diseases.

It has also been tested in more than 250 patients in multiple NIH and Heat-funded oncology trials.